A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis

S. Clark, E. Tindall, Robert (Rob) Bennett

    Research output: Contribution to journalArticle

    159 Citations (Scopus)

    Abstract

    Twenty patients with a diagnosis of fibrositis were entered into a double blinded crossover study to compare the effects of prednisone versus placebo. Each patient was randomly assigned to either prednisone 15 mg/day or placebo for 14 days of therapy and then therapy was switched for a further 14 days. The following measurements were assessed at baseline, end of Week 2 and end of Week 4: analogue scores for pain, sleep disturbance, morning stiffness and fatiguability, and dolorimetry readings of pain tolerance over 14 representative tender joints. Overall there was no improvement while taking prednisone, indeed most measured variables showed a trend towards deterioration with this therapy.

    Original languageEnglish (US)
    Pages (from-to)980-983
    Number of pages4
    JournalJournal of Rheumatology
    Volume12
    Issue number5
    StatePublished - 1985

    Fingerprint

    Fibromyalgia
    Prednisone
    Cross-Over Studies
    Placebos
    Pain
    Reading
    Sleep
    Therapeutics
    Joints

    ASJC Scopus subject areas

    • Immunology
    • Rheumatology

    Cite this

    A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. / Clark, S.; Tindall, E.; Bennett, Robert (Rob).

    In: Journal of Rheumatology, Vol. 12, No. 5, 1985, p. 980-983.

    Research output: Contribution to journalArticle

    Clark, S. ; Tindall, E. ; Bennett, Robert (Rob). / A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. In: Journal of Rheumatology. 1985 ; Vol. 12, No. 5. pp. 980-983.
    @article{39b11b2f7a414e2e82611c5bc4cd13cc,
    title = "A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis",
    abstract = "Twenty patients with a diagnosis of fibrositis were entered into a double blinded crossover study to compare the effects of prednisone versus placebo. Each patient was randomly assigned to either prednisone 15 mg/day or placebo for 14 days of therapy and then therapy was switched for a further 14 days. The following measurements were assessed at baseline, end of Week 2 and end of Week 4: analogue scores for pain, sleep disturbance, morning stiffness and fatiguability, and dolorimetry readings of pain tolerance over 14 representative tender joints. Overall there was no improvement while taking prednisone, indeed most measured variables showed a trend towards deterioration with this therapy.",
    author = "S. Clark and E. Tindall and Bennett, {Robert (Rob)}",
    year = "1985",
    language = "English (US)",
    volume = "12",
    pages = "980--983",
    journal = "Journal of Rheumatology",
    issn = "0315-162X",
    publisher = "Journal of Rheumatology",
    number = "5",

    }

    TY - JOUR

    T1 - A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis

    AU - Clark, S.

    AU - Tindall, E.

    AU - Bennett, Robert (Rob)

    PY - 1985

    Y1 - 1985

    N2 - Twenty patients with a diagnosis of fibrositis were entered into a double blinded crossover study to compare the effects of prednisone versus placebo. Each patient was randomly assigned to either prednisone 15 mg/day or placebo for 14 days of therapy and then therapy was switched for a further 14 days. The following measurements were assessed at baseline, end of Week 2 and end of Week 4: analogue scores for pain, sleep disturbance, morning stiffness and fatiguability, and dolorimetry readings of pain tolerance over 14 representative tender joints. Overall there was no improvement while taking prednisone, indeed most measured variables showed a trend towards deterioration with this therapy.

    AB - Twenty patients with a diagnosis of fibrositis were entered into a double blinded crossover study to compare the effects of prednisone versus placebo. Each patient was randomly assigned to either prednisone 15 mg/day or placebo for 14 days of therapy and then therapy was switched for a further 14 days. The following measurements were assessed at baseline, end of Week 2 and end of Week 4: analogue scores for pain, sleep disturbance, morning stiffness and fatiguability, and dolorimetry readings of pain tolerance over 14 representative tender joints. Overall there was no improvement while taking prednisone, indeed most measured variables showed a trend towards deterioration with this therapy.

    UR - http://www.scopus.com/inward/record.url?scp=0022340869&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0022340869&partnerID=8YFLogxK

    M3 - Article

    VL - 12

    SP - 980

    EP - 983

    JO - Journal of Rheumatology

    JF - Journal of Rheumatology

    SN - 0315-162X

    IS - 5

    ER -